Diagnostic and prognostic biomarkers for progressive fibrosing interstitial lung disease

被引:4
|
作者
Watase, Mayuko [1 ]
Mochimaru, Takao [1 ,2 ]
Kawase, Honomi [1 ]
Shinohara, Hiroyuki [1 ]
Sagawa, Shinobu [1 ]
Ikeda, Toshiki [1 ]
Yagi, Shota [1 ]
Yamamura, Hiroyuki [1 ]
Matsuyama, Emiko [1 ]
Kaji, Masanori [1 ]
Kurihara, Momoko [1 ]
Sato, Midori [1 ]
Horiuchi, Kohei [1 ]
Watanabe, Risa [1 ]
Nukaga, Shigenari [1 ]
Irisa, Kaoru [1 ]
Satomi, Ryosuke [1 ]
Oyamada, Yoshitaka [1 ,2 ]
机构
[1] Natl Hosp Org Tokyo Med Ctr, Dept Resp Med, Tokyo, Japan
[2] Natl Hosp Org Tokyo Med Ctr, Dept Allergy, Tokyo, Japan
来源
PLOS ONE | 2023年 / 18卷 / 03期
关键词
PULMONARY-FIBROSIS;
D O I
10.1371/journal.pone.0283288
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
No biomarkers have been identified in bronchoalveolar lavage fluid (BALF) for predicting fibrosis progression or prognosis in progressive fibrosing interstitial lung disease (PF-ILD). We investigated BALF biomarkers for PF-ILD diagnosis and prognosis assessment. Overall, 120 patients with interstitial pneumonia who could be diagnosed with PF-ILD or non PF-ILD were enrolled in this retrospective study. PF-ILD was diagnosed according to Cottin's definition. All patients underwent bronchoscopy and BALF collection. We evaluated blood and BALF parameters, high-resolution computed tomography (HRCT) patterns, and spirometry data to identify factors influencing PF-ILD diagnosis and prognosis. On univariate logistic analysis, age, sex, the BALF white blood cell fraction (neutrophil, lymphocyte, eosinophil, and neutrophil-to-lymphocyte ratio), BALF flow cytometric analysis (CD8), and an idiopathic pulmonary fibrosis/usual interstitial pneumonia pattern on HRCT were correlated with PF-ILD diagnosis. Multivariate logistic regression analysis revealed that sex (male), age (cut-off 62 years, area under the curve [AUC] 0.67; sensitivity 0.80; specificity 0.47), white blood cell fraction in BALF (NLR, neutrophil, and lymphocyte), and CD8 in BALF (cut-off 34.2; AUC 0.66; sensitivity, 0.74; specificity, 0.62) were independent diagnostic predictors for PF-ILD. In BALF, the NLR (cut-off 8.70, AUC 0.62; sensitivity 0.62; specificity 0.70), neutrophil count (cut-off 3.0, AUC 0.59; sensitivity 0.57; specificity 0.63), and lymphocyte count (cut-off 42.0, AUC 0.63; sensitivity 0.77; specificity 0.53) were independent diagnostic predictors. In PF-ILD patients (n = 77), lactate dehydrogenase (cut-off 275, AUC 0.69; sensitivity 0.57; specificity 0.78), Krebs von den Lungen-6 (cut-off 1,140, AUC 0.74; sensitivity 0.71; specificity 0.76), baseline forced vital capacity (FVC) (cut-off 1.75 L, AUC 0.71; sensitivity, 0.93; specificity, 0.46), and BALF neutrophil ratio (cut-off 6.0, AUC 0.72; sensitivity 0.79; specificity 0.80) correlated with death within 3 years. The BALF cellular ratio, particularly the neutrophil ratio, correlated with the diagnosis and prognosis of PF-ILD. These findings may be useful in the management of patients with interstitial pneumonia.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype
    Inoue, Yoshikazu
    Kaner, Robert J.
    Guiot, Julien
    Maher, Toby M.
    Tomassetti, Sara
    Moiseev, Sergey
    Kuwana, Masataka
    Brown, Kevin K.
    CHEST, 2020, 158 (02) : 646 - 659
  • [2] Frequency and Prognostic Impact of Progressive Fibrosing Phenotype of Interstitial Lung Disease
    Takei, R.
    Yamano, Y.
    Kataoka, K.
    Yokoyama, T.
    Matsuda, T.
    Kimura, T.
    Suzuki, A.
    Kondoh, Y.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [3] Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis
    Bowman, Willis S.
    Newton, Chad A.
    Linderholm, Angela L.
    Neely, Megan L.
    Pugashetti, Janelle Vu
    Kaul, Bhavika
    Vo, Vivian
    Echt, Gabrielle A.
    Leon, William
    Shah, Rupal J.
    Huang, Yong
    Garcia, Christine Kim
    Wolters, Paul J.
    Oldham, Justin M.
    LANCET RESPIRATORY MEDICINE, 2022, 10 (06): : 593 - 602
  • [4] Prevalence of progressive fibrosing interstitial lung disease
    Olson, Amy
    Hartmann, Nadine
    Schlenker-Herceg, Rozsa
    Wallace, Laura
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [5] Prevalence of Progressive Fibrosing Interstitial Lung Disease
    Charest-Morin, Xavier
    Olson, Amy
    Wallace, Laura
    Hartmann, Nadine
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 823 - 823
  • [6] Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response
    Bowman, Willis S.
    Echt, Gabrielle A.
    Oldham, Justin M.
    FRONTIERS IN MEDICINE, 2021, 8
  • [7] Lung function trajectory in progressive fibrosing interstitial lung disease
    Oldham, Justin M.
    Lee, Cathryn T.
    Wu, Zhe
    Bowman, Willis S.
    Pugashetti, Janelle Vu
    Dao, Nam
    Tonkin, James
    Seede, Hasan
    Echt, Gabrielle
    Adegunsoye, Ayodeji
    Chua, Felix
    Maher, Toby M.
    Garcia, Christine K.
    Strek, Mary E.
    Newton, Chad A.
    Molyneaux, Philip L.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 59 (06)
  • [8] Burden of illness in progressive fibrosing interstitial lung disease
    Singer, David
    Bengtson, Lindsay G. S.
    Conoscenti, Craig S.
    Anderson, Amy J.
    Brekke, Lee
    Shetty, Sharash S.
    Brown, Kevin K.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2022, 28 (08): : 871 - 880
  • [9] The Role of Radiology in Progressive Fibrosing Interstitial Lung Disease
    Abu Qubo, Ahmad
    Capaccione, K. M.
    Bernstein, Elana J.
    Padilla, Maria
    Salvatore, Mary
    FRONTIERS IN MEDICINE, 2022, 8
  • [10] Progressive fibrosing interstitial lung disease in hypersensitivity pneumonitis
    Alberti, M. L.
    Malet Ruiz, J. M.
    Fassola, L.
    Auteri, S.
    Fernandez, M.
    Donati, P.
    Caro, F.
    EUROPEAN RESPIRATORY JOURNAL, 2022, 60